Prevalence and correlates of apathy in myotonic dystrophy type 1

Benjamin Gallais, Michèle Montreuil, Marcela Gargiulo, Bruno Eymard, Cynthia Gagnon, Luc Laberge, Benjamin Gallais, Michèle Montreuil, Marcela Gargiulo, Bruno Eymard, Cynthia Gagnon, Luc Laberge

Abstract

Background: Apathy in DM1 has long been acknowledged in clinical practice. However, a major drawback is that the concept has been only sparsely explored in previous specific studies. This study aimed to determine the prevalence of apathy in myotonic dystrophy (DM1), to compare it with facioscapulohumeral dystrophy (FSHD) patients and normal healthy controls, and explore its relationship to psychopathological features and cognitive function.

Methods: Levels of apathy in 38 DM1 patients with adult phenotypes were compared with 19 patients with FSHD and 20 matched controls. Patient participants were consecutively recruited, regarding their interdisciplinary annual evaluation at the neuromuscular pathology reference center (Institute of Myology, Paris, France), within an 18-month period. Additional measurements included motor disability, fatigue, depression, anxiety, and cognitive abilities. Inter-group comparisons were performed using non-parametric Kruskal-Wallis tests and Mann-Whitney U Tests. Intra-group comparisons were carried out with the Wilcoxon Signed rank and Friedman tests. Also, Spearman's correlations were used to assess the strength of linear relationships between pairs of variables. The significance level was set at 0.05.

Results: Global score of apathy was significantly higher in DM1 patients than in FSHD patients (p < 0.01) and in controls (p < 0.001). Sixteen of 38 DM1 patients (39.5 %) met the criterion for apathy, contrasting with only 4 of the 19 (21.1 %) FSHD patients. No control subject was apathetic. Moreover, apathy in DM1 patients was negatively correlated to MMSE (r = -.46, p < .05) and Stroop Word (r = -.55, p < .01) scores, but not with age, educational level, disease duration, CTG repeats, motor functional disability, fatigue, depression, and anxiety.

Conclusions: Apathy is a frequent symptom in DM1 (almost 40 %). It is more prevalent than in a similarly disabled group of patients with FSHD and in controls. Results also show that apathy in DM1 is independent of the psychopathological domain, fatigue, age, and motor disability, but associated to general cognitive status. These results altogether could suggest a central cause for apathy in DM1 rather than an adjustment process to cope with the progressive and debilitating nature of the disease. Data emphasize the importance to evaluate this symptom in routine clinical management of DM1 patients.

References

    1. Harper P. Myotonic dystrophy. 3. London: WB Saunders; 2001.
    1. Gagnon C, Chouinard MC, Jean S, Laberge L, Veillette S, Bégin P, Breton R, Brisson D, Gaudet D, Mathieu J, DM1 Expert Panel Health supervision and anticipatory guidance in adult myotonic dystrophy type 1. Neuromuscul Disord. 2010;20:847–51. doi: 10.1016/j.nmd.2010.08.006.
    1. Brook JD, McCurrach ME, Harley HG, Buckler AJ, Church D, Aburatani H, Hunter K, Stanton VP, Thirion JP, Hudson T, et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3′ end of a transcript encoding a protein kinase family member. Cell. 1992;69:385.
    1. Harley HG, Rundle SA, MacMillan JC, Myring J, Brook JD, Crow S, Reardon W, Fenton I, Shaw DJ, Harper PS. Size of the unstable CTG repeat sequence in relation to phenotype and parental transmission in myotonic dystrophy. Am J Hum Genet. 1993;52:1164–74.
    1. Angeard N, Gargiulo M, Jacquette A, Radvanyi H, Eymard B, Héron D. Cognitive profile in childhood myotonic dystrophy type 1: is there a global impairment? Neuromuscul Disord. 2007;17:451–8. doi: 10.1016/j.nmd.2007.02.012.
    1. Winblad S, Lindberg C, Hansen S. Cognitive deficits and CTG repeat expansion size in classical myotonic dystrophy type 1 (DM1) Behav Brain Funct. 2006;2:16. doi: 10.1186/1744-9081-2-16.
    1. Sistiaga A, Urreta I, Jodar M, Cobo AM, Emparanza J, Otaegui D, Poza JJ, Merino JJ, Imaz H, Marti-Masso JF, Lopez de Munain A. Cognitive/personality pattern and triplet expansion size in adult myotonic dystrophy type 1 (DM1): CTG repeats, cognition and personality in DM1. Psychol Med. 2009;40:487–95. doi: 10.1017/S0033291709990602.
    1. Meola G, Sansone V, Perani D, Scarone S, Cappa S, Dragoni C, Cattaneo E, Cotelli M, Gobbo C, Fazio F, et al. Executive dysfunction and avoidant personality trait in myotonic dystrophy type 1 (DM-1) and in proximal myotonic myopathy (PROMM/DM-2) Neuromuscul Disord. 2003;13:813–21. doi: 10.1016/S0960-8966(03)00137-8.
    1. Winblad S, Lindberg C, Hansen S. Temperament and character in patients with classical myotonic dystrophy type 1 (DM-1) Neuromuscul Disord. 2005;15:287–92. doi: 10.1016/j.nmd.2004.12.003.
    1. Rohrer K. Myotonia atrophica (dystrophica myotonica) Deutsche Zeitung von Nerven. 1916;55:242–8. doi: 10.1007/BF01733055.
    1. Thomasen E. Myotonia. Aarhus: Universitetsforlaget; 1948.
    1. Bungener C, Jouvent R, Delaporte C. Psychopathological and emotional deficits in myotonic dystrophy. J Neurol Neurosurg Psychiatry. 1998;65:353–6. doi: 10.1136/jnnp.65.3.353.
    1. Rubinsztein JS, Rubinsztein DC, Goodburn S, Holland AJ. Apathy and hypersomnia are common features of myotonic dystrophy. J Neurol Neurosurg Psychiatry. 1998;64:510–5. doi: 10.1136/jnnp.64.4.510.
    1. Di Costanzo A, Mottola A, Toriello A, Di Iorio G, Tedeschi G, Bonavita V. Effects of the antiarrhythmic drug hydroquinidine on apathy and hypersomnia. Neurol Sci. 2000;21:81–6. doi: 10.1007/s100720070100.
    1. Sistiaga A, Camano P, Otaegui D, Ibanez B, Ruiz-Martinez J, Marti-Masso JF, Lopez de Munain A. Cognitive function in facioscapulohumeral dystrophy correlates with the molecular defect. Genes Brain Behav. 2009;8:53–9. doi: 10.1111/j.1601-183X.2008.00442.x.
    1. Koch MC, Grimm T, Harley HG, Harper PS. Genetic risks for children of women with myotonic dystrophy. Am J Hum Genet. 1991;48:1084–91.
    1. Gardner-Medwin D. The clinical examination of the voluntary muscles. In: Walton JN, editor. Disorders of voluntary muscles. Edinburgh and London: Churchill-Livingstone; 1974.
    1. Sockeel P, Dujardin K, Devos D, Deneve C, Destee A, Defebvre L. The Lille apathy rating scale (LARS), a new instrument for detecting and quantifying apathy: validation in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2006;77:579–84. doi: 10.1136/jnnp.2005.075929.
    1. Amorim P, Lecrubier Y, Weiller E, Hergueta T, Sheehan D. Concordance and causes for discordance with the CIDI. Eur Psychiatry. 1998;13:26–34. doi: 10.1016/S0924-9338(97)86748-X.
    1. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382–9. doi: 10.1192/bjp.134.4.382.
    1. Spielberger CD. Manual for the State-Trait Anxiety Inventory (form Y) (“self-evaluation questionnaire”) Palo Alto, CA: Consulting Psychologists Press; 1983.
    1. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–98. doi: 10.1016/0022-3956(75)90026-6.
    1. Golden CJ. Stroop color and word test: a manual for clinical and experimental uses. Chicago, Illinois: Skoelting; 1978.
    1. Stroop JR. Studies of interference in serial verbal reactions. J Exp Psychol. 1935;18:643–62. doi: 10.1037/h0054651.
    1. Tombaugh TN. Trail making Test A and B: normative data stratified by age and education. Arch Clin Neuropsychol. 2004;19:203–14. doi: 10.1016/S0887-6177(03)00039-8.
    1. Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a Frontal Assessment Battery at bedside. Neurology. 2000;55:1621–6. doi: 10.1212/WNL.55.11.1621.
    1. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46:1121–3. doi: 10.1001/archneur.1989.00520460115022.
    1. Marin RS, Biedrzycki RC, Firinciogullari S. Reliability and validity of the apathy evaluation scale. Psychiatry Res. 1991;38:143–62. doi: 10.1016/0165-1781(91)90040-V.
    1. Hilton-Jones D, Damian M, Meola G. Myotonic Dystrophy: present management, future therapy. New York: Oxford University Press; 2004. Somnolence and its management; pp. 135–49.
    1. Hilton-Jones D, Bowler M, Lochmueller H, Longman C, Petty R, Roberts M, Rogers M, Turner C, Wilcox D. Modafinil for excessive daytime sleepiness in myotonic dystrophy type 1--the patients’ perspective. Neuromuscul Disord. 2012;22:597–603. doi: 10.1016/j.nmd.2012.02.005.
    1. Levy ML, Cummings JL, Fairbanks LA, Masterman D, Miller BL, Craig AH, Paulsen JS, Litvan I. Apathy is not depression. J Neuropsychiatry Clin Neurosci. 1998;10:314–9. doi: 10.1176/jnp.10.3.314.
    1. Dujardin K, Sockeel P, Devos D, Delliaux M, Krystkowiak P, Destee A, Defebvre L. Characteristics of apathy in Parkinson’s disease. Mov Disord. 2007;22:778–84. doi: 10.1002/mds.21316.
    1. Levy R, Czernecki V. Apathy and the basal ganglia. J Neurol. 2006;253(Suppl 7):VII54–61.
    1. Winblad S, Jensen C, Mansson J-E, Samuelsson L, Lindberg C. Depression in myotonic dystrophy type 1: clinical and neuronal correlates. Behav Brain Funct. 2010;6:25. doi: 10.1186/1744-9081-6-25.
    1. Starkstein SE, Jorge R, Mizrahi R, Robinson RG. A prospective longitudinal study of apathy in Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2006;77:8–11. doi: 10.1136/jnnp.2005.069575.
    1. Varanese S, Perfetti B, Ghilardi MF, Di Rocco A. Apathy, but not depression, reflects inefficient cognitive strategies in Parkinson’s disease. PLoS One. 2011;6:e17846. doi: 10.1371/journal.pone.0017846.
    1. Esposito F, Rochat L, Van der Linden AC, Lekeu F, Quittre A, Charnallet A, Van der Linden M. Apathy and executive dysfunction in Alzheimer disease. Alzheimer Dis Assoc Disord. 2010;24:131–7. doi: 10.1097/WAD.0b013e3181c9c168.
    1. Stuss DT, Van Reekum R, Murphy KJ. Differentiation of states and causes of apathy. In: Borod JC, editor. The neuropsychology of emotion. Oxford: Oxford University Press; 2000. pp. 340–63.
    1. Gagnon C, Mathieu J, Jean S, Laberge L, Perron M, Veillette S, Richer L, Noreau L. Predictors of disrupted social participation in myotonic dystrophy type 1. Arch Phys Med Rehabil. 2008;89:1246–55. doi: 10.1016/j.apmr.2007.10.049.
    1. Meola G, Sansone V. Cerebral involvement in myotonic dystrophies. Muscle Nerve. 2007;36:294–306. doi: 10.1002/mus.20800.
    1. Dujardin K, Sockeel P, Delliaux M, Destee A, Defebvre L. The Lille Apathy Rating Scale: validation of a caregiver-based version. Mov Disord. 2008;23:845–9. doi: 10.1002/mds.21968.
    1. Burgess PW. Strategy application disorder: the role of the frontal lobes in human multitasking. Psychol Res. 2000;63:279–88. doi: 10.1007/s004269900006.
    1. Bechara A, Damasio H, Damasio AR. Emotion, decision making and the orbitofrontal cortex. Cereb Cortex. 2000;10:295–307. doi: 10.1093/cercor/10.3.295.
    1. Alderman N, Burgess PW, Knight C, Henman C. Ecological validity of a simplified version of the multiple errands shopping test. J Int Neuropsychol Soc. 2003;9:31–44.
    1. Thomas P, Clement JP, Hazif-Thomas C, Leger JM. Family, Alzheimer’s disease and negative symptoms. Int J Geriatr Psychiatry. 2001;16:192–202. doi: 10.1002/1099-1166(200102)16:2<192::AID-GPS301>;2-Y.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe